Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABBOTT EXTENDING INFUSION PUMP LINE

Executive Summary

ABBOTT EXTENDING INFUSION PUMP LINE with LifeCare 1500 ambulatory microinfuser, developed and manufactured by Parker Hannifin, Abbott an- nounced in a May 15 release. Abbott said it "signed an agreement to market an ambulatory medication infusion pump developed by Parker Hannifin. . .to further extend its leading line of products that deliver intravenous fluids and drugs to patients electronically." Parker Hannifin said that Abbott would have exclusive marketing rights to the device as long as certain undisclosed conditions are met. Parker Hannifin will produce the device, which will either be leased or sold to physicians and hospitals at a cost ranging between $1,400 and $2,000, for Abbott. The microinfusion pump, Abbott's fourth electronic flow device in the LifeCare line, will be marketed separately from Abbott drug products, the firm said. Abbott's other pump devices include the LifeCare Model 4 pump, micro pump, 1050 volumetric controller, and a patient-controlled analgesia system. The programmable electronic infusion device, approved by the FDA 16 months ago, "will be used to provide drugs to patients being treated for cancer, pain and infectious diseases," the release states. The device is "smaller than a business card" and weighs "less than 2-1/2 ounces," according to the release.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS008329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel